



is partly dependent on
mitochondrial calcium
uniporter activity
E Fernández-Sada1*, C Silva-Platas1*, C A Villegas1, S L Rivero1,
B C Willis1, N García1,2, J R Garza1, Y Oropeza-Almazán1, C A Valverde3,
G Mazzocchi3, C Zazueta4, G Torre-Amione1,2,5 and G García-Rivas1,2
1Cátedra de Cardiología y Medicina Vascular, Escuela de Medicina, Tecnológico de Monterrey,
Monterrey, Nuevo León, México, 2Centro de Investigación Básica y Transferencia, Instituto de
Cardiología y Medicina Vascular, Tec Salud, San Pedro Garza García, Nuevo León, México,
3Centro de Investigaciones Cardiovasculares, Facultad de Ciencias Médicas, Universidad Nacional
de La Plata, La Plata, Argentina, 4Departamento de Biomedicina Cardiovascular, Instituto
Nacional de Cardiología ‘Ignacio Chávez’, México City, D.F., México, and 5Methodist DeBakey
Heart and Vascular Center, The Methodist Hospital, Houston, TX, USA
Correspondence
Dr Gerardo García-Rivas, Centro
de Investigación Básica y
Transferencia, Instituto de
Cardiología y Medicina Vascular,
Tec Salud, Batallón de San
Patricio 112, Hospital
Zambrano-Hellión, Edificio
Escuela de Medicina, 2do, Nivel,
San Pedro Garza García CP













Despite the importance of mitochondrial Ca2+ to metabolic regulation and cell physiology, little is known about the
mechanisms that regulate Ca2+ entry into the mitochondria. Accordingly, we established a system to determine the role of the
mitochondrial Ca2+ uniporter in an isolated heart model, at baseline and during increased workload following β-adrenoceptor
stimulation.
EXPERIMENTAL APPROACH
Cardiac contractility, oxygen consumption and intracellular Ca2+ transients were measured in ex vivo perfused murine hearts.
Ru360 and spermine were used to modify mitochondrial Ca2+ uniporter activity. Changes in mitochondrial Ca2+ content and
energetic phosphate metabolite levels were determined.
KEY RESULTS
The addition of Ru360, a selective inhibitor of the mitochondrial Ca2+ uniporter, induced progressively and sustained negative
inotropic effects that were dose-dependent with an EC50 of 7 μM. Treatment with spermine, a uniporter agonist, showed a
positive inotropic effect that was blocked by Ru360. Inotropic stimulation with isoprenaline elevated oxygen consumption
(2.7-fold), Ca2+-dependent activation of pyruvate dehydrogenase (5-fold) and mitochondrial Ca2+ content (2.5-fold). However,
in Ru360-treated hearts, this parameter was attenuated. In addition, β-adrenoceptor stimulation in the presence of Ru360 did
not affect intracellular Ca2+ handling, PKA or Ca2+/calmodulin-dependent PK signalling.
CONCLUSIONS AND IMPLICATIONS
Inhibition of the mitochondrial Ca2+ uniporter decreases β-adrenoceptor response, uncoupling between workload and
production of energetic metabolites. Our results support the hypothesis that the coupling of workload and energy supply is
partly dependent on mitochondrial Ca2+ uniporter activity.
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Introduction
Cardiac excitation–contraction coupling consumes enor-
mous amounts of cellular energy, which is mainly produced
in mitochondria by oxidative phosphorylation. In order to
support the constantly varying workload with energy supply,
coordinated mechanisms are essential to maintain the avail-
ability of energetic phosphate metabolites (Maack and
O’Rourke, 2007; Balaban, 2009). Intramitochondrial calcium
([Ca2+]m) has drawn attention as being a key player in the
coupling of mitochondrial ATP production to cardiac work-
load. When a cardiac workload is imposed, the cytosolic-free
calcium ([Ca2+]c) increases, which in turn results in [Ca2+]m
increase, an event that triggers activation of key dehydroge-
nases of the citric acid cycle, to match the production of
NADH to its oxidation by the electron transport chain
(McCormack et al., 1990). This series of events is essential for
a proper regulation of energy production and cardiac contrac-
tility. A critical step in this process is the uptake of Ca2+ from
the cytosol into the mitochondria and neither the mecha-
nisms nor the regulators that control this process are fully
defined. Cytosolic Ca2+ influx into the mitochondrial matrix
is mediated primarily by the highly selective calcium
channel, mitochondrial Ca2+ uniporter (MCU) (Gunter and
Pfeiffer, 1990). Functional and comparative genomics has
led to the characterization of the MCU complex, which
includes the channel-forming subunit MCU (Baughman
et al., 2011; De Stefani et al., 2011) and its regulators MICU1,
MICU2, MCUb, EMRE and MCUR1 (Perocchi et al., 2010;
Mallilankaraman et al., 2012; Raffaello et al., 2013; Sancak
et al., 2013), which are crucial for Ca2+ uptake.
While it is clear that this cluster of proteins has the capac-
ity of transporting Ca2+ from the cytosol into the mitochon-
dria in a large number of cell types, whether they play a role
in normal cardiac cells is not known. In fact, because of the
high speed of systolic Ca2+ transients in heart cells, the role of
the MCU as a key regulator of the entry of Ca2+ into the
mitochondria on a beat-to-beat mechanism remains a matter
for debate (O’Rourke and Blatter, 2009).
But a series of observations from our group are in support
of the central role of the MCU as a regulator of cardiac
physiology and are germane to this discussion. First, in a
model of cardiac ischaemia-reperfusion injury, treatment
with Ru360, a selective inhibitor of the MCU, prevented mito-
chondrial Ca2+ overload (García-Rivas et al., 2006). Second,
isolated mitochondria obtained from Ru360-treated hearts
decreased [Ca2+]m (García-Rivas et al., 2005) and, finally,
Ru360-treated hearts following ischaemia-reperfusion injury
were less prone to undergo mitochondria permeability tran-
sition and apoptosis (García-Rivas et al., 2006; Correa et al.,
2007). Taking these observations together suggests that the
MCU plays a critical role in intramitochondrial Ca2+ han-
dling at least in pathological conditions. However, the role of
MCU under conditions of normal or physiological increases
in contractility is not known. Accordingly, we set up a series
of experiments with rat isolated hearts to determine the
regulatory role of the MCU under unstimulated conditions
of heart contractility and following β-adrenoceptor stimula-
tion, assuming that an increase in [Ca2+]m is essential for
increasing ATP supply. Here, we identified that MCU inhibi-
tion results in a lower response to β-adrenoceptor stimula-
tion and uncoupling of workload and myocardial oxygen
consumption (MVO2). We conclude that coupling of the




All animal care and experimental procedures were in accord-
ance with the animal care guidelines of the Guide for the
Care and Use of Laboratory Animals published by the US
National Institutes of Health and approved by the animal use
and care committees of the School of Medicine of the Tec-
nológico de Monterrey (Project Nos. 2009-R006 and F2011-
009) and La Plata University. All studies involving animals are
reported in accordance with the ARRIVE guidelines for
reporting experiments involving animals (Kilkenny et al.,
2010; McGrath et al., 2010). A total of 67 rats and 10 mice
were used in the experiments described here. Male Wistar rats
(250–300 g) were obtained from the Tecnológico de Monter-
rey campus Animal Facility. Mice (17–28 g) were obtained
from the La Plata Medical School animal facility. Animals
were allowed free access to food and water and maintained
on a 12-h light/dark cycle, with controlled temperature
(22.5 ± 2°C ) and humidity (45 ± 5%).
Rat isolated perfused hearts
The hearts were mounted in accordance with the Langendorff
model and perfused at constant flow (12 mL·min−1) with
Krebs–Henseleit (K-H) buffer that consisted of (in mM): 3.5
KCl, 116 NaCl, 26 NaHCO3, 1.6 NaH2PO4, 0.7 MgSO4, 1.5
CaCl2, 11 glucose and 0.2 octanoate. The buffer was gassed
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with 95% O2-5% CO2 and equilibrated at pH 7.4, 37°C
(García-Rivas et al., 2005). The pulmonary artery was cannu-
lated and connected to a closed chamber to measure MVO2 in
the coronary effluent with a Clark-type oxygen electrode
(Yellow Spring Instruments, Yellow Spring, OH, USA). The
rate of MVO2 was calculated as the difference between the
concentration in the K-H buffer before (100%) and after per-
fusion. To obtain an isovolumetrically beating preparation, a
latex balloon filled with water and connected by a catheter
transducer was used (FOBS-28; WPI, Sarasota, FL, USA). Before
each experimental protocol was initiated, the isolated hearts
were set at a mean left ventricular pressure (LVP) of 60 ±
10 mmHg and were allowed to stabilize and wash out the
potential residual catecholamines for 10–15 min. Heart rate
(HR), LVP, mechanical performance index (MPi) (HR*LVP),
and maximum positive and negative derivatives of LVP (±dP/
dt) and MVO2 were continuously recorded with Data Trax
software (WPI). At the end of protocols, the atrial or ventricu-
lar tissue was removed from the perfusion system and imme-
diately flash-frozen with liquid N2, weighed and stored at
−80°C.
Isolation of cardiomyocytes
Hearts were removed and mounted on the Langendorff
apparatus as described above, and then perfused with
collagenase-containing solution (1 mg·mL−1 collagenase
type II; Worthington, Lakewood, NJ, USA) at 37°C as previ-
ously described (MacDonnell et al., 2008). After enzymic
treatment, the ventricles were dissected and mechanically
disaggregated. Dissociated cells were filtered and rinsed in
modified Tyrode buffer (composition in mM: 5.4 KCl, 128
NaCl, 0.4 NaH2PO4, 0.5 MgCl2, 25 HEPES, 1.8 CaCl2, 6
glucose, 5 creatine and 5 taurine, pH. 7.4 equilibrated with
100% O2.
Measurement of mitochondrial Ca2+
Frozen cardiac tissue from each experimental group was used
to determine fractional activation of the pyruvate dehydro-
genase (PDHa) (PDHa/PDHTotal) [E.C.1.2.4.1] as an indicator
of [Ca2+]m, according to previous publications (Pepe et al.,
1999). We assessed PDH activity under extraction buffers in
which both PDH phosphatase and PDH kinase were inhibited
by KH2PO4, NaF, dichloroacetic acid and ADP. PDH activity
was assessed spectrophotometrically following NADH pro-
duction at 340 nm and 30°C (Pepe et al., 1999). Mitochondria
were prepared from isolated hearts by a rapid isolation
method that was designed to minimize Ca2+ redistribution. At
the end of each protocol, the heart was perfused with an
ice-cold buffer containing (in mM) 250 sucrose, 1 EGTA,
0.001 diltiazem, 0.002 Ru360, 0.002 cyclosporine A and 10
HEPES, pH 7.4, and was homogenized with a Polytron.
[Ca2+]m was measured by using the fluorescent indicator,
Fluo-3 AM, assuming a dissociation constant, KD = 310 nM, as
described previously (García-Rivas et al., 2005).
Measurement of Ca2+ transients
Ventricular cells were incubated for 30 min in Tyrode solu-
tion containing Fluo-3 AM (5 μM) and afterwards washed
with a fluorophore-free solution. Fluorescent measurements
were acquired with a Leica TCS SP5 confocal microscope,
equipped with a D-156 apochromatic X63, 1.2 NA, oil
objective. An argon laser was used to excite the fluorophore at
488 nm and emission collected at 500–600 nm. Line scan
images were recorded along the longitudinal axis of the cell at
500 Hz. For Ca2+ transients, cells were field stimulated at 1 Hz.
Fluorescence data were normalized as F/F0, where F is fluores-
cence intensity and F0 is average fluorescence at rest
(MacDonnell et al., 2008).
Perfused isolated hearts from mice were prepared accord-
ing to Valverde et al. (2006). Rhod-2 (Invitrogen, Carlsbad,
CA, USA) was used to evaluate intracellular calcium in the
epicardial layer of the isolated hearts from mice using a
custom-made setup for pulse local-field fluorescence (PLFF)
microscopy. After dye loading and stabilization, hearts were
paced at 5 Hz and perfused with Tyrode solution, as previ-
ously reported (Valverde et al., 2006) with 0.5, 1 and 2 mM
Ca2+ in the absence or presence of Ru360. Ratio between
emitted (F–F0) and basal (F0) fluorescence (ΔF/F0) was com-
pared with 2 mM Ca2+ transient amplitude.
Quantification of energetic
phosphate metabolites
Rat heart samples fast-frozen in liquid nitrogen were
extracted by homogenizing in ice-cold 40% perchloric acid
containing 0.5 mM EGTA. After 10 min on ice, the acid
extract was centrifuged at 10 000× g for 2 min, and an aliquot
of the supernatant was neutralized with KOH to pH 6.8.
Within 1 h of extraction, the sample was thawed and used for
HPLC separation and determination of energetic phosphate
metabolites. After chromatographic separation, the peak area
of each nucleotide in the chromatogram of the sample
without added reference standards was subtracted from the
corresponding peak area in the chromatogram of the sample
with added standard nucleotides. Under these conditions the
recovery of reference nucleotides and bases ranged from 90%.
Nucleotide analyses were carried out with a dual-pump gra-
dient HPLC system (Waters Chromatography, Toronto,
Canada) as previously described (Ally and Park, 1992). Stand-
ard solutions were prepared in 0.1 M KH2PO4, pH 7.0, and
stored at −80°C to minimize the degradation of phosphocrea-
tine (PCr). The standard curves were subjected to linear
regression analysis and calibration factors were determined.
Measurement of oxidative stress and GSH
Frozen cardiac tissue from each group was used to determine
the activity of the aconitase [E.C.4.2.1.3] by monitoring the
NADP+ reduction (340 nm) by isocitrate dehydrogenase [EC
1.1.1.42] upon addition of (in mM) 1 sodium citrate, 0.6
MnCl2, 0.2 NADP+ and 1 U·mL−1 isocitrate dehydrogenase [EC
2.7.11.5] as previously reported (Silva-Platas et al., 2012).
Membrane lipid peroxidation was analysed by measuring the
generation of thiobarbituric acid-reactive substances (TBARS)
and reduced GSH in heart extracts was quantified utilizing
the GSH-Glo GSH assay from Promega (Madison, WI, USA).
NADP+ and NADPH in heart tissue was extracted under acidic
(0.4 M HCl) or basic (carbonate buffer, pH 11) conditions and
extracts were neutralized to pH 7.5. The quantification was
carried out with the GloTM assay (Promega). Concentration
was obtained creating a standard curve for each component
and expressed in nmol·mg−1 protein.
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cAMP and PKA activity assay
Heart homogenates were obtained from atria or ventricles in
lysis buffer [(in mM) 20 MOPS, 50 β-glycerolphosphate, 50
NaF, 1 sodium vanadate, 5 EGTA, 2 EDTA, 1 DTT, 1 benzami-
dine, 1 PMSF, 1% NP40, 10 mg·mL−1 leupeptin and aprotinin]
using a Polytron at 10 000 r.p.m. After centrifugation at
11 000× g, the supernatant was collected. cAMP levels were
determined using complete ELISA kit (ENZO Life Sciences,
Farmingdale, NY, USA) following manufacturer’s instruction.
PK activity was determined using PKA activity kit (ENZO Life
Sciences) using 200 and 400 ng per well of the phospho-
specific substrate antibody and the anti-rabbit IgG HRP con-
jugate respectively.
Western blots of phospholamban (PLB)
Heart homogenates from atria or ventricles (15 μg) were
resolved by SDS-PAGE as previously described (Benkusky
et al., 2007). Blocked membranes were incubated at 4°C for
10 h in PBS-T with antibodies to PLB-pThr17 (1:5000; Santa
Cruz Biotechnology, Santa Cruz, CA, USA) or anti-PBL
(1:1000; Abcam, Cambridge, UK). Membranes were washed
three times in PBS-T for 10 min. After washing, membranes
were incubated with the respective secondary antibody anti-
IgG (Millipore, Billerica, MA, USA) conjugated to HRP in
PBS-T for 2 h. After washing three times for 10 min, protein–
antibody reactions were detected using the Clarity Western
ECL substrate (Bio-Rad, Hercules, CA, USA) and the UVP
Image Acquisition System. The level of phosphorylation was
expressed as the ratio of the intensities of the phospho-signal
for each antibody to the anti-PLB signal.
Data analysis
Pooled data are presented as mean ± SEM. Single or paired
Student’s t-test was used to determine the statistical signifi-
cance of the data. ANOVA test was used for comparisons among
treatments. Pearson product-moment correlation was used
for correlation among variables. P ≤ 0.05 was considered
statistically significant.
Materials
Ru360 (μ-oxo)bis(trans-formatotetramine ruthenium) was syn-
thesized following the procedure described by Ying et al.
(1991). Ru360 concentration after chemical synthesis was cal-
culated from the molar extinction coefficient of the complex
at 360 nm (ξ = e 2.6 × 104 M−1·cm−1), as described by others
(Matlib et al., 1998; Zazueta et al., 1999). All other materials
were from Sigma, except for Fluo-3AM and Rhod-2 that were
supplied by Invitrogen.
Results
Ru360 – a specific blocker of MCU – decreases
cardiac contractility and MVO2
Acute effects of Ru360 on MPi and MVO2 were analysed in the
rat isolated heart preparation. Figure 1A shows a time course
of Ru360 effect on heart contractility. MPi was measured in
hearts of untreated controls (open circles) and in the presence
of 5 μM Ru360 (solid circles). In the presence of Ru360, cardiac
contractility was rather slow and gradual; the diminution of
MPi began within 10 min of perfusion, peaked between 30
and 45 min and was still significant at 60 min. The time for
half-inhibition (t0.5) by Ru360 is given in Table 1. Panel B of
Figure 1 illustrates the representative recordings of heart per-
formance in control (left) and 5 μM Ru360 (right) perfused
hearts at 30 min. Ru360 treatment produced a significant
reduction in heart contractility, shown as a decrease (45%) of
left ventricular pressure (LVP), an increase in HR of 20%, and
a decrease in 30% MPi and 18% MVO2, compared with the
control. Increasing doses of Ru360 were administered via the
perfusate solution of isolated heart preparations during
30 min. Figure 2A shows the dose-dependent effects of Ru360
on MPi and MVO2. The maximal inhibitory effect of Ru360 was
observed at 200 μM and the IC50 is shown in Table 1. Panel B
shows that, in Ru360-treated hearts, relaxation rate decreased
whereas the contraction rate was preserved. In addition, the
kinetics parameters of Ru360 showed an 11-fold diminution on
IC50 on relaxation versus contraction rate (Table 1), suggest-
ing a preferential effect of Ru360 on cardiac relaxation.
Figure 2C shows a concentration-dependent effect of Ru360 on
Ca2+ transients of isolated cardiomyocytes. Ventricular myo-
cytes perfused with Tyrode buffer and stimulated at 1 Hz
exhibit normal contraction and peak Ca2+ transients before
treatment with 0.5 μM Ru360 (upper panel). The maximal
inhibitory effect of Ru360 was observed at 50 μM and the
half-maximal inhibitory concentration (IC50) was 7.1 ±
0.9 μM. Perfusion of the cells with 15 μM Ru360 for up to
30 min significantly decreased the amplitude of [Ca2+]c and
cell shortening (not shown). The results suggest that Ru360 at
submicromolar concentration does not affect normal [Ca2+]c
transients and shortening of isolated cardiac myocytes. Panel
D shows HR response. As illustrated, Ru360 caused a dose-
dependent increase in the HR. This was evident as early as
10 min following administration of Ru360. This interesting
finding might indicate that changes in mitochondrial Ca2+
transport will affect the cardiac pacemaker automaticity in
accordance to a recent paper (Yaniv et al., 2012). We charac-
terized the effects of Ru360 on PKA and Ca2+/calmodulin-
dependent PK (CaMKII) signalling as this signalling pathway
regulates the firing rate of the sinoatrial node action potential
(Lakatta et al., 2010). First, we measured cAMP levels and PKA
activity in atrial tissue treated with isoprenaline (100 nM)
during 10 min and observed a significant twofold increase in
cAMP (Supporting Information Fig. S1). Ru360 treatment did
not affect the cAMP production and PKA activity following
isoprenaline stimulation. Perfusion with isoprenaline also
increased CaMKII activity, shown as phosphorylated PLB-
Thr17 (Supporting Information Fig. S1C). Ru360 treatment
increased phosphorylated PBL in response to isoprenaline,
indicating that the CaMKII pathway increased in Ru360-
treated atrial tissue, causing a positive chronotropic effect.
Spermine (Spm), an allosteric activator of
mitochondrial Ca2+ uptake, causes a positive
inotropic effect in rat heart
To support the identity of MCU as the molecular entity
responsible for the effects described above, we performed
additional experiments with a known MCU agonist. Rat iso-
lated hearts were perfused with various concentrations of
Spm, a permeable activator of MCU (Brunton et al., 1990;
Gunter and Pfeiffer, 1990). As shown in Figure 3A, Spm
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(50 μM) increased the MPi in a time-dependent manner, (t0.5
inTable 1), whereas the untreated controls showed no
change. The maximal stimulation was achieved and sus-
tained after 5–10 min of Spm perfusion. Therefore, at 10 min
of Spm treatment, we obtained a dose-dependent positive
inotropic effect on MPi and MVO2, with half-maximal effec-
tive concentration (EC50) around 55 ± 7 and 136 ± 48 μM
respectively (Figure 3B). The kinetic properties of Spm on
relaxation and contraction rate had shown a similar EC50
(Table 1) suggesting positive inotropic and lusitropic effects.
Activation of Ca2+ uptake from mitochondria by Spm progres-
sively reduced the HR to 16% control over a 10 min period at
2 mM. Note that the effects of Spm on chronotropy were the
opposite od those after the MCU inhibitor (Figure 3C). In
Figure 4A, upper panel, we present a time course of MPi in
control hearts. In the presence of Spm (50 μM), a rapid
increase in MPi was observed (Figure 4A, middle panel). Pre-
treatment for 30 min with 5 μM Ru360 in the perfusate
blocked the Spm-positive inotropic effect (Figure 4A, lower
panel). Spm treatment increased MPi and MVO2 by 35 and
40% respectively but Ru360 still decreased the stimulation by
Spm (Figure 4B and C). In addition, perfusion with Spm (50
μM) increased both PDHa activity and [Ca2+]m and these
changes were almost totally prevented by Ru360 treatment
(Figure 4D and E). Simultaneous co-treatment of Spm and
Ru360 failed to block Spm-positive inotropic effect (data not
shown) probably due to slow and gradual Ru360 effect. All
together, these results suggest that the positive inotropic
effect of Spm could be dependent on mitochondrial calcium
transport.
Ru360 decreased the inotropic effect of
isoprenaline in isolated hearts
The role of MCU in cardiac contractility was further charac-
terized by applying isoprenaline to isolated hearts to activate
β1-adrenoceptors, with or without Ru360. As shown in
Figure 5A, isoprenaline increased contractility concentration-
dependently, but Ru360-treated hearts failed to increase MPi,
HR, +dP/dt and −dP/dt in response to isoprenaline (Figure 5B
and C). In ventricular tissue, we examined whether Ru360
action was mediated by activation of PKA signalling.
Although isoprenaline (100 nM) increased cAMP (Figure 6A).
Ru360 treatment did affect this response. Similarly, the PKA
and CaMKII activity after isoprenaline was not affected by
Ru360 (Figure 6B and C).
Ru360 decreased MVO2 and [Ca2+]m during
responses to β-adrenoceptor stimulation
During isoprenaline treatment, the amplitude of cytosolic
Ca2+ transient increases, and with it the energy demand in the
cell. To exclude the possibility that Ru360 may have negatively
affected cytosolic Ca2+ handling in ventricular cells, and
Figure 1
Ru360 has negative inotropic effects on unstimulated isolated rat
hearts. Panel A shows a time course of Ru360 effect on heart contrac-
tility. MPi was measured in untreated hearts (controls) or withRu360
(5 μM). In the presence of Ru360, cardiac contractility diminished
gradually after 10 min of perfusion and reached the lowest at
45 min. The time for half-inhibition (t0.5) of Ru360 was 21 ± 3 min.
Panel B shows representative recordings of heart performance at
30 min of perfusion in control (left) and 5 μM Ru360 (right) hearts.
Ru360 treatment produced a significant reduction in heart contractil-
ity, indicated by the decrease of LVP accompanied by a slight increase
in heart rate. The MPi and MVO2 were lower after RU360 than in
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Table 1
Dose and time dependent constants on hearts treated with mitochondrial Ca2+ uptake modulators
Time-dependent constants (min)
Ru360 Spm
MPi (×1000) (mmHg·beat·min−1) t0.5 21 ± 3 1.7 ± 0.3
Dose-dependent constants (μM)
MPi (×1000) (mmHg·beat·min−1) IC50 7 ± 3 –
EC50 – 55 ± 7
MVO2 (μmolO2·min−1·g−1) IC50 17 ± 9 –
EC50 – 136 ± 48
+dP/dt (×1000) IC50 15 ± 3 –
EC50 – 48 ± 9
−dP/dt (×1000) IC50 1.3 ± 0.5 –
EC50 – 21 ± 6





























































































































The effects of Ru360 on heart contractility, oxygen consumption, chronotropy and Ca+2 transient are concentration-dependent. Increasing doses
of Ru360 were administered via the perfusate of isolated heart preparations during 30 min. Panel A shows the concentration-dependent effect of
Ru360 on MPi and MVO2. The maximal inhibitory effect of Ru360 was observed at 200 μM and the IC50 for Ru360 was 7 ± 3 μM. Panel B shows the
+dP/dt and −dP/dt in Ru360-treated hearts. The relaxation rate decreased with 5 μM Ru360, while preserving the contraction rate (3.4 ± 0.5 vs. 3.3
± 0.4 (×1000) mmHg × s−1). Panel C shows the effect on Ca+2 transients in isolated cardiomyocytes. Upper panel represents a representative
recording of Ca+2 transients at 0 (vehicle), 0.5 and 15 μM of Ru360. Lower panel shows the concentration-dependent effect on the peak Ca+2
transient before 30 min of treatment with Ru360. The half inhibitory dose is 7.1 ± 0.9 μM. In panel D, treatment with Ru360 caused a
concentration-dependent increase in the HR, evident as early as 10 min after starting perfusion with Ru360. Values are the mean ± SEM (at least
n = 5 experiments for each dose). *P ≤ 0.05, significantly different from baseline.
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consequently reduced MPI and MVO2, we recorded Ca2+ tran-
sients in isolated hearts from mice. Isolated hearts were
loaded with Rhod-2 and electrically evoked Ca2+ transients in
epicardial ventricular myocytes were visualized with PLFF
microscopy. Figure 6, panel D, shows representative record-
ings of control and Ru360-treated hearts. The Ca2+ transients
recorded in control hearts exhibited normal contraction and
peak Ca2+ transients before treatment with 0.5 μM Ru360. Aver-
aged data (Figure 6, panel D) indicate a similar effect on Ca2+
transient amplitude in control and Ru360-treated hearts during
extracellular Ca2+ increase. The duration of Ca2+ transient at
half-maximum amplitude (t50) was not different between
groups (data not shown). Thus, Ru360 treatment did not
reduce contractile properties through negative effects on Ca2+
handling. During the perfusion with isoprenaline, MVO2
increased 2.7-fold but isoprenaline in Ru360-treated hearts
(0.5 μM) failed to increase MVO2 (Figure 7A). In panel B, we
show a linear relationship between MPi and MVO2 that rep-
resents cardiac efficiency, in the two sets of heart [slope in
control hearts = 0.53 ± 0.02 vs. Ru360-treated slope (r) = 0.98 ±
0.08, P < 0.01].
Panels C, D show the PDH activity (PDHa) in heart
homogenates and [Ca2+]m in isolated mitochondria respec-
tively. During β-adrenoceptor stimulation, PDHa activity
increased fivefold versus control. Remarkably, PDHa activity
in Ru360-treated hearts with isoprenaline was 43% lower than
in control hearts treated with isoprenaline. [Ca2+]m was sig-
nificantly increased by isoprenaline (2.5-fold) compared with
control hearts. This effect was almost blocked in the Ru360-
treated hearts. There were no significant changes in myocar-
dial PCr and ATP after isoprenaline in control or Ru360-treated
hearts (panels E, F). These findings suggest that the feedback
mechanism between ATP demand (e.g. ATPase activity in the
myofibrils) and production in the mitochondria is highly
buffered (Katz et al., 1989). Even the slight changes in the
Ru360 + isoprenaline hearts may suggest a local diminution
that affects heart contractility.As shown in Figure 8, we found
an exponential relationship between MPi and PDHa activity
or MVO2 suggesting that MPi was dependent on MCU activ-
ity. Changes in PDHa activity have shown that modification
on MCU activity caused variations in cardiac contractility (r =
0.961, P = 0.002). Modifications of MVO2 had shown a similar
relationship with MCU agonist or blockers (r = 0.962, P =
0.002). All these data suggest that [Ca2+]m must play a role in
the feedback mechanism between energy production and
MPi in the heart, and that the MCU plays a relevant role on
this metabolic–mechanical coupling, in particular during
mechanical overload.
The negative inotropic effect induced by Ru360
is not dependent on oxidative stress
A recent paper identified a previously unrecognized role of
mitochondrial Ca2+ uptake for the control of mitochondrial
reactive oxygen species (ROS), triggered by oxidation of
NADPH (Kohlhaas et al., 2010). This ROS formation was
potentiated when mitochondrial Ca2+ uptake was blocked
with Ru360. To explore this as a possible mechanism for
impaired response to β-adrenoceptor stimulation in Ru360-
treated hearts, we measured NADP+/NADPH, GSH levels and
TBARS formation. We observed that neither Ru360, Spm nor
isoprenaline treatment elicited significant pro-oxidant action
on isolated hearts; and differently from Kohlhaas et al.’s
(2010) results on isolated cells, we found that in Ru360-treated
hearts the NADP+/NADPH ratio did not change (control 1.1 ±
0.1; Ru360 treatment (0.5 μM) 0.9 ± 0.07; ISO (1 nM) 1.2 ±
0.02; Ru360 treatment +ISO 1.3 ± 0.02 nmol·mg−1), and neither
did GSH levels (Ru360 treatment 1.7 ± 0.6; Spm (50 μM) 1.5 ±
0.8; ISO 2.2 ± 0.5 nmol·mg−1). The sensitivity of aconitase
activity was not diminished under these conditions (Ru360
treatment 47 ± 5; Spm 58 ± 4; ISO 42 ± 4 nmol NADPH per
min·mg−1) and there was no evidence for oxidative damage to
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Spermine (Spm), an allosteric activator of mitochondrial Ca2+ uptake,
exerted positive inotropic effects on rat heart. Isolated hearts were
perfused with various concentrations of Spm a permeable activator
of the MCU. In panel A, Spm (50 μM) increases the MPi in a time-
dependent manner, with a time for half-effective (t0.5) of 1.7 ±
0.3 min. Untreated controls did not change. The maximal stimula-
tion was achieved and sustained after 5–10 min of Spm perfusion. In
panel B, the concentration-dependent, positive inotropic effect of
Spm, measured at 10min, on MPi and MVO2, with EC50 around 55 ±
7 and 136 ± 48 μM respectively. Heart rate did not change impor-
tantly during Spm perfusion (panel C). Values are the mean ± SEM
(n = 5–6 experiments for each treatment). *P ≤ 0.05, significantly
different from control.
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phospholipids of the membranes, as assayed by TBARS (Ru360
treatment 3.3 ± 0.9; Spm 2.5 ± 0.3; isoprenaline 2.8 ±
0.4 nmol TBARS per mg). According to these data, there was
a decrease of [Ca2+]m but this was not accompanied by an
increased ROS production.
Discussion and conclusions
In this study, we provided evidence that supported the role of
the MCU as a key regulator in cardiac contractility as well as
defining its critical role in β-adrenoceptor stimulation. First,
we found that, in an isolated heart model, Ru360, a selective
inhibitor of MCU, induced progressive and sustained nega-
tive inotropic effects. Second, in the same model, Spm, an
MCU agonist, exerted positive inotropic effects that were
blocked by Ru360. Finally, the inotropic effects induced by
β-adrenoceptor stimulation were partly blocked by the addi-
tion of Ru360. This effect in ventricular tissue was not medi-
ated by changes in PKA or CaMKII signalling. Taken together,
these findings showed that MCU inhibition lowered
responses to β-adrenoceptor stimulation, resulting from
uncoupling of workload and production of energetic phos-
phate metabolites. Our results support the hypothesis that
coupling between workload and energy supply is partly
dependent on MCU activity.
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The stimulatory effect of spermine (Spm) in heart contractility is prevented by the early perfusion of Ru360. Control values of MPi are represented
in panel A, upper figure. In the presence of Spm (50 μM), MPi rapidly increased (Figure A, middle panel). Pretreatment with Ru360 (5 μM) in the
perfusate blocked the positive inotropic effects of Spm (Figure A, lower panel). Comparisons made for MPi and MVO2 of data extracted from panel
A experiments are represented in panels B and C respectively. Significant differences are presented as (a) versus control, (b) versus 5 μM Ru360
treatment, (c) versus Spm treatment, and (d) versus Ru360 + Spm treatment. Direct measurements of pyruvate dehydrogenase activity (PDHa) in
heart homogenates at the end of perfusion protocol are presented in panel D. Intramitochondrial calcium was determined in mitochondria
isolated from hearts at the end of perfusion protocol (panel E). Values are the mean ± SEM (n = 5–6 experiments for each treatment). *P ≤ 0.05,
significantly different from control, ANOVA.
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The role of MCU in cardiac contractility
Ru360 is commonly used as a specific inhibitor of the MCU
with the purpose of studying mitochondrial Ca2+ transport
and its physiological role. For example, when Ru360 (5–10 μM)
is added to the external solution, it inhibits mitochondrial
Ca2+ uptake in intact rat (Belmonte and Morad, 2008) and
ferret myocytes (Zhou and Bers, 2002; Jo et al., 2006), without
affecting sarcoplasmic reticulum Ca2+ transport, L-type Ca2+
channels or sarcolemmal Na+/Ca2+ exchanger activity (Matlib
et al., 1998). Others have found that Ru360 does not appear to
enter into adult (Maack et al., 2006) or neonatal (Bell et al.,
2006) cardiomyocytes because it had no effect on the mito-
chondrial Ca2+ transients observed in these cells.
However, Matlib et al. (1998) measured the uptake of
radioactive 103Ru360 into isolated rat ventricular myocytes and
found a slow uptake. Over 30 min, the authors estimated the
cytosolic [Ru360] to be 100 nM, which would be sufficient to
completely inhibit MCU. Experiments on ferret myocytes
under similar conditions showed that incubation for 30 min
with 10 μM Ru360 inhibited Ca2+ uptake into mitochondria
induced by cell depolarization (Zhou and Bers, 2002). In
isolated guinea pig ventricular myocytes, 10 μM Ru360 largely
attenuated both the metabolic response and mitochondrial
Ca2+ transients (Jo et al., 2006).
In this regard, our experiments on Ru360-treated isolated
hearts also showed a slow effect with a time constant (21 ±
3 min), similar to previous experiments in intact cardiomyo-
cytes (Figure 1 and Table 1). Importantly, several observations
suggest that the use of Ru360 is associated with cardiac protec-
tion in conditions where cell injury is produced by Ca2+
overload. For example, the addition of Ru360 protects hearts or
myocytes from Ca2+ overload at concentrations ranging from
0.2 to 6 μM (García-Rivas et al., 2005; Zhang et al., 2006;
Correa et al., 2007; Ragone and Consolini, 2009). Pretreat-
ment of rat isolated hearts with Ru360 provided protection
against reperfusion injury, as shown by mechanical param-
eters, infarct size and intracellular enzymes release
(García-Rivas et al., 2005, 2006; Shintani-Ishida et al., 2012).
Further, we previously reported that lower concentrations of
Ru360 were required to reduce mitochondrial matrix Ca2+,
indicating that Ru360 partly blocks MCU ex vivo (García-Rivas
et al., 2005). In the present study, we observed that Ru360
produced a potent and gradual negative effect on cardiac
workload and MVO2 (IC50 = 7 ± 3 μM). Additionally, activa-
tion of the MCU with Spm increased the cardiac workload
and pretreatment with Ru360 abolished this effect of Spm,
suggesting that mitochondrial Ca2+ uptake has a role on
modulating cardiac workload (Figure 3C). Recently, the
molecular nature of the channel has been identified as a
result of progress in genome sequencing. An RNAi screening
allowed the identification of the MCU protein, and other
MCU regulator proteins known as MICU1 and MICU2,
MCUR1, MCUb and EMRE (Perocchi et al., 2010; Baughman
et al., 2011; De Stefani et al., 2011; Mallilankaraman et al.,
2012; Raffaello et al., 2013; Sancak et al., 2013). In this regard,
at the cellular level, overexpression of MCU increased the rate
of Ca2+ uptake and this sensitized the cells to death following
Ca2+ overload (Baughman et al., 2011); these results were con-
sistent with pharmacological studies using Ru360 (Correa et al.,
2007). But more importantly, recent observations from our
laboratory indicated that MCU protein is expressed differen-
tially in the normal human heart and in disease states (G.
García-Rivas et al., unpublished). A very recent study by Poz-
zan’s group used genetic silencing of the MCU in neonatal
cardiomyocytes, and observed that, during spontaneous
pacing, [Ca2+]m decreased while [Ca2+]c and contraction
increased. Therefore, in neonatal myocytes, these data
support the idea that MCU could serve as a spatial Ca2+ buffer
and thus affect the magnitude and the amplitude of the
increase of systolic Ca2+ (Drago et al., 2012). However, in the
present study, blocking MCU with Ru360 significantly reduced










































































Ru360 decreases the inotropic effect of isoprenaline in isolated hearts.
Isolated hearts were treated with various concentrations of isoprena-
line (ISO), with or without Ru360 (panel A); data are shown at 30 min
of perfusion.Treatment with isoprenaline increased the contractility
in a concentration-dependent manner. Early perfusion with 0.5 μM
Ru360 blocked the full inotropic response to isoprenaline. Panels B and
C show HR and relaxation and contraction rate (±dP/dt) of isolated
perfused hearts treated with isoprenaline (100 nM) with or without
Ru360. The increased MPi, chronotropy and lusitropy (−dP/dt) trig-
gered by isoprenaline were lower in Ru360-treated hearts. Values are
the mean ± SEM (n = 5–6 experiments for each treatment). Signifi-
cant differences (P ≤ 0.05) are presented as (a) versus control, (b)
versus Ru360 treatment, (c) versus isoprenaline treatment, and (d)
versus Ru360 + isoprenaline treatment; ANOVA.
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study reflect not only differences between adult and neonatal
cardiac cells, but also the different experimental models
employed, that is, isolated single pacemaker cells in the
earlier study and intact hearts in the present study. A very
useful tool for obtaining direct insights into the role of MCU
in cardiac contractility in the whole heart would be the spe-
cific knockout animal model for this protein, as has recently
described (Pan et al., 2013).
β-adrenoceptor stimulation and MCU activity
The heart needs a cellular mechanism to increase and or
balance the PCr/ATP ratio to meet the demand for energetic
metabolites, for instance during the increased workload pro-
duced by β-adrenoceptor stimulation. Early studies in isolated
mitochondria found that the ADP/ATP ratio was the main
regulator of ATP production, but studies in beating hearts
found that the ratio between PCr/ATP did not change in ex
vivo hearts, even during large increases in workload (Portman
et al., 1989).
The findings of the present study are in support of the
latter idea that, independent of increased workload caused by
β-adrenoceptor stimulation, PCr/ATP levels in beating hearts
were remarkably constant (Figure 7E and F). In contrast, an
exponential correlation between PDH activity and MCU
activity was found (Figure 8), indicating that Ca2+ could acti-
vate mitochondrial dehydrogenases like PDH. Our findings
support the hypothesis that an increase in the supply of
reducing equivalents, in the form of NADH and FADH2,
would increase ATP production (Jo et al., 2006), and is con-
sistent with a model in which [Ca2+]i regulates both the uti-
lization of energetic metabolites by the work-producing
ATPases, as well as the mitochondrial production of ATP.
In this study, we found that MCU inhibition restricted
workload stimulation due to decreased Ca2+ uptake into mito-
chondria (Figure 7D); however, we observed that cardiac effi-
ciency in Ru360-treated hearts (Figure 7B) was energetically
improved. This exciting result could imply that cardiac work-
load and PCr/ATP ratio were maintained even though no
increase in [Ca2+]m occurred, and suggested that increases in
[Ca2+]m play an alternative role under stimulation workload.
In this regard, Territo et al. (2000) demonstrated that Ca2+
added to previously Ca2+-depleted cardiac mitochondria























































































































Integrity of downstream β-adrenoceptor signalling and intracellular Ca2+ handling during Ru360 perfusion. In panel A, the intracellular content of
cAMP in homogenates of ventricles from hearts perfused with isoprenaline (ISO; 100 nM) for 10 min was increased fourfold. Ru360 treatment
(0.5 μM) for 30 min did not affect cAMP production in response to isoprenaline stimulation. In panel B, PKA activity in hearts perfused with
isoprenaline was not affected by Ru360. In panel C, Western blots of the phosphorylation of phospholamban at Thr17 are shown. In panel D, isolated
mouse hearts loaded with Rhod-2 were used to evaluate intracellular calcium in the epicardial layer, using PLFF microscopy. Upper recording shows
the trace of the transient for control and lower recording (0.5 μM) Ru360 perfusion. Ca2+ is increased during perfusion to verify the experiment
outcome. Inset panel shows the transient amplitude normalized to the value of 2 mM Ca+2 for the transient for control and for Ru360 treated hearts.
Values are the mean ± SEM (n = 4–7 experiments for each treatment). Significant differences (P ≤ 0.05) are presented as (a) versus control, (b)
versus Ru360 treatment, (c) versus isoprenaline treatment, and (d) versus Ru360 + isoprenaline treatment.
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ATPase modulating the ΔΨ (Territo et al., 2000). Thus, Ca2+ is
capable of increasing the capacity of ATP production by the
F1-F0-ATPase at a constant driving force simultaneously with
the increased delivery of NADH. Similar to our results, the
half-maximal effect of Ca2+ was inhibited by MCU blockers,
indicating matrix dependence of the Ca2+ effect (Territo et al.,
2000; Sun et al., 2009). Furthermore, it has been shown that
ΔΨ decreases during Ca2+ mobilization in HeLa cells (Poburko
et al., 2011). Ca2+ transport to mitochondria can elevate res-
piration possibly due to an increase in the mitochondrial
matrix volume, which in turn can produce swelling in iso-
lated mitochondria (Halestrap, 1987). However, in isolated
cardiomyocytes, the increase in [Ca2+]c during low electrical
stimulation (1 Hz) did not increase mitochondrial volume,
suggesting that, at resting or low workloads, mitochondrial
swelling does not serve to facilitate this purpose (Yaniv
et al., 2011). Nevertheless, during increased workload after
β-adrenoceptor stimulation, volume-activated Ca2+ transport
into mitochondria might increase in response to increases
in myofilament strain to couple ATP supply and demand.
Therefore, it is possible that during cardiac workload, an
increase in Ca2+ serves to facilitate this purpose. Possibly,
Ru360-treated hearts, which are resistant to mitochondrial
swelling and permeability transition (García-Rivas et al.,



















































































































Ru360 decreases oxygen consumption and [Ca2+]m during β-adrenoceptor stimulation. Isolated hearts were treated with increasing concentrations
of isoprenaline (ISO) with or without Ru360 (0.5 μM). As shown in panel A, isoprenaline (ISO) increased MVO2 and this response was absent in
Ru360-treated hearts. Panel B shows the relationship between MPi and MVO2. Panels C and D show the pyruvate dehydrogenase activity (PDHa)
in heart homogenates and [Ca2+]m in isolated mitochondria respectively. PDHa activity increased after isoprenaline and this increase was blocked
by Ru360. [Ca2+]m was also increased by isoprenaline and this effect was almost abolished by Ru360. In panels E, F, isoprenaline did not change
myocardial PCr or ATP and Ru360 did not affect this lack of response. Values are the mean ± SEM (n = 5–6 experiments for each treatment).
Significant differences (P ≤ 0.05) are presented as (a) versus control, (b) versus isoprenaline treatment, and (c) versus Ru360 + isoprenaline
treatment; ANOVA.
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Recently, Lakatta’s group suggested that mitochondrial
Ca2+ transport modulated chronotropism in pacemaker cells
(Yaniv et al., 2012). These results indicated that mitochon-
drial Ca2+ dynamics acted as a buffer of cytosolic Ca2+, which
therefore affected sarcoplasmic reticulum Ca2+ handling,
leading to changes in spontaneous action potential. In
accordance with those results, a similar effect of Ru360 on HR
was documented in our study (Figure 2, panel D) and stimu-
lates mitochondrial Ca2+ uptake with Spm that mimicked the
bradycardic effect of CGP37157 (blocker of mitochochondrial
Na+/Ca2+ exchanger) on sinoatrial node cells. Chronotropic
effects during β-adrenoceptor stimulation involve PKA and
CaMKII-dependent phosphorylation of multiple proteins on
sinoatrial node cells; furthermore, ATP production must
increase to maintain high spontaneous action potential firing
rate (Yaniv et al., 2011). In this regard, a recent study from
Yaniv et al. demonstrated that increased chronotropism was
accompanied by an increase in MVO2, ATP synthesis, [Ca2+]m
and cAMP. Similar to our results, when MCU was blocked by
Ru360, the increased chronotropism in response to isoprena-
line was reduced.
Moreover, in atrial tissue treated with isoprenaline and
Ru360, CaMKII activity was increased (Supporting Information
Fig. S1). However, in ventricular tissue, MCU inhibition did
not modify PKA and CaMKII signalling (Figure 6). This
differential tissue-specific result might have several ex-
planations, including differential PKA/CaMKII-Ca2+ signal-
ling between pacemakers and ventricular cardiomyocytes
(Lakatta et al., 2010). For instance, Joiner et al., (2012) have
recently demonstrated that MCU is a phosphorylation sub-
strate CaMKII and that CaMKII phosphorylation increases
MCU activity. Another possibility could be including differ-
ential expression levels of MCU and regulatory accessory
proteins or NCXm between sinoatrial cells and ventricular
cardiomyocytes.
The present findings demonstrate, for the first time, that
the modulation of MCU in isolated hearts correlated with
impaired metabolic responses to cardiac stimulation. The
ability of the MCU inhibitor to improve energy efficiency may
have several underlying mechanisms. (1) When an abrupt
change of workload was simulated by β-adrenoceptor stimu-
lation, ATP hydrolysis is increased, which increases the avail-
ability of ADP and Pi to stimulate ATP production. (2)
Consumption of ΔΨ by F1-F0-ATPase to stimulate electron
transport, proton pumping, and the rate of NADH/FADH2
oxidation at the onset of workload. (3) At the same time, the
increase of amplitude of [Ca2+]c transients promotes mitochon-
drial Ca2+ uptake through MCU, activating key dehydroge-
nases of the TCA cycle to supply reducing equivalents. Figure 9
is a schematic representation of the general idea on how [Ca2+]c
links sarcoplasmic reticulum and mitochondria during
β-adrenoceptor stimulation , emphasizing the role of MCU.
Implications
Impairment of intracellular Ca2+ homeostasis and mitochon-
drial function has been implicated in the development of
heart failure, and abundant studies have identified decreased
cardiac energy levels and lower flux as consistent features of
heart failure (Neubauer, 2007). Mitochondria isolated from
failing hearts showed a reduced Ca2+ uptake and this was
associated with a lower membrane potential and reduced
activities of respiratory complexes (Lin et al., 2007). Further-
more, recent work from O’Rourke’s group demonstrated that
inhibiting the mitochondrial Na+/Ca2+ exchanger in a guinea
pig model of heart failure increased [Ca2+]m and activation of
Ca2+-dependent dehydrogenases, such as PDH. It is likely to
restore ATP levels in the failing hearts regulating [Ca2+]m
(Sullivan et al., 2006; Liu and O’Rourke, 2008). In addition,
Michels et al. (2009) showed in the mitochondrial inner
membrane from failing hearts that mitochondrial Ca2+ trans-
port decreased in failing, compared with non-failing, human
hearts. These results suggest that mitochondria from failing
hearts were less effective in Ca2+ uptake and, consequently, in
activation of Ca2+-induced metabolism, which may explain,
at least partly, the reduced myocardial energetic phosphate
metabolite levels in heart failure. In this context, the MCU is
a feasible target for treatment of conditions where ATP syn-
thesis is impaired, such as in cardiomyopathies and heart
failure. Activators of MCU could be used to increase [Ca2+]m as
this may be of benefit in heart failure., We therefore need
pharmacological activators of MCU with greater specificity,
given that Spm has other effects, for instance, on the regula-
tion of cell proliferation and differentiation (Lee and
MacLean, 2011).
On the other hand, the principal clinical manifestations
of advanced heart failure are reduced systolic and diastolic
functions, exacerbated by an excessive sympathetic
activation and extensive abnormalities in β-adrenoceptor
signalling (Braunwald and Bristow, 2000). In this regard,
the reduced workload stimulation in MCU-blocked hearts
suggests a condition similar to that observed in heart
failure and indicates that MCU activity could lead to the
uncoupling of mitochondrial metabolism from energy
demand during cardiac stimulation. The recent identification
MPi (x1000)
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Figure 8
MCU activity couples mechanical to metabolic responses in the
isolated heart. Changes in pyruvate dehydrogenase (PDHa) activity
are associated with the modification of MCU activity and these with
variations in cardiac contractility (r = 0.961, P = 0.002). Modifications
of oxygen consumption (MVO2) show a similar relationship with
MCU agonist or blockers (r = 0.962, P = 0.002). The MCU activity was
modified using 5 μM and 0.5 μM Ru360, 20 μM spermine, 100 nM
isoprenaline, 0.5 μM Ru360 + 100 nM isoprenaline. Pearson product-
moment correlation was used to test for correlation among variables.
Values are the mean ± SEM (n = 5 experiments for each treatment).
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of the molecular components of the MCU opens new possi-
bilities in the clarification of the role of mitochondrial Ca2+
homeostasis on excitation–contraction and energetic cou-
pling in normal and failing hearts and represents a fertile area
of research in the future.
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Scheme of the mechanism by which mitochondrial Ca2+ uniporter (MCU) contributes to cardiac workload. In ventricular myocytes, on
β-adrenoceptor stimulation, cAMP-dependent PKA and Ca2+/calmodulin-dependent PK (CaMKII) signalling is activated, which augments con-
tractility and Ca2+ transients. In close proximity with mitochondria, ryanodine receptors (RyR) in the sarcoplasmic reticulum release Ca2+ into the
mitochondrial intermembranal space and makes it available for uptake into the matrix by the MCU. This transmembrane protein consists of two
transmembrane domains and a pore-forming region that contains Ser259, a target for the inhibitory effect of Ru360 (Baughman et al., 2011). In
addition, mitochondrial Ca2+ uptake 1 and 2 (MICU1 and MICU2, respectively), MCUR1, MCUb and essential MCU regulator (EMRE) proteins act
as regulators of this channel (Perocchi et al., 2010; Mallilankaraman et al., 2012; Raffaello et al., 2013; Sancak et al., 2013). The rise in
intramitochondrial Ca2+ activates the Krebs cycle dehydrogenases (CaDH) increasing the capacity for the production of NADH. The respiratory
chain oxidizes NADH and consumes O2 (MVO2) in order to establish the proton gradient for the production of ATP by oxidative phosphorylation.
ATP is removed from mitochondria through the creatine kinase system. These events match the energy demand during the response to
β-adrenoceptor stimulation . Therefore, inhibition of MCU impaired the cardiac workload. On the other hand, in sinoatrial node cells (dotted lines),
mitochondrial Ca2+ flux [MCU and Na+/Ca2+ exchanger (NCXm)] translates into a change in the action potential firing rate by effecting changes
in cAMP/PKA/CamKII signalling, cytosolic Ca2+ and sarcoplasmic reticulum Ca2+ loading, which affects heart chronotropism.
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Figure S1 Integrity of downstream β-adrenoceptor signal-
ling during Ru360 perfusion in atrial tissue. We measured
cAMP levels (panel A) and PKA activity (panel B) in atrial
tissue treated with isoprenaline (ISO; 100 nM) during 10 min.
We observed a significant twofold increase in cAMP and PKA
activity. Panel C shows the phosphorylation of PLB-Thr17.
Ru360 treatment significantly increased PLB phosphorylation
residues in response to isoprenaline, indicating that the
CaMKII pathway could increase in Ru360-treated atrial tissue,
causing a positive chronotropic effect.
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